Syros Pharmaceuticals Inc (SYRS) - News Archive

Showing 9 of 9 results.

Syros Pharmaceuticals, Inc. (NASDAQSYRS), based in Cambridge, Massachusetts, continues to pioneer advanceme...

Syros Pharmaceuticals Announces Strategic Business Restructuring and Clinical Trial Developments Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), based in Cambridge, Massachusetts, continues to pioneer advancements in the fie...

Mar 2, 2025 • Major Pharmaceutical Preparations Industry Business Update NASDAQ Pomerantz L Pomerantz L Levi August

Syros Pharmaceuticals Faces Challenge with SELECT-MDS-1 Phase 3 Trial Results, Yet Remains Focused on Future Growth

Syros Pharmaceuticals, a biopharmaceutical company specializing in the development of treatments for hematologic malignancies, recently announced topline data from their SELECT-MDS-1 Phase 3 trial. The trial investigate...

Nov 13, 2024 • Major Pharmaceutical Preparations Industry Business Update NASDAQ Pomerantz L Pomerantz L Levi August

Syros Pharmaceuticals, a leading biopharmaceutical company specializing in the treatment of hematologic mal...

Syros Pharmaceuticals Reports Second Quarter 2024 Financial Results: A Summary of Revenue Decline and Business UpdatesSyros Pharmaceuticals, a leading biopharmaceutical company specializing in the treatment of hematolog...

Jul 24, 2024 • Major Pharmaceutical Preparations Industry Business Update NASDAQ

Syros Pharmaceuticals Reports Strong First Quarter 2024 Financial Results and Advances Tamibarotene for Frontline Treatment of Hematologic Malignancies

Syros Pharmaceuticals, a leading biopharmaceutical company dedicated to improving treatment options for hematologic malignancies, recently released its financial results for the first quarter of 2024. The company also s...

May 14, 2024 • Major Pharmaceutical Preparations Industry Business Update NASDAQ

Breakthrough or Bustn Syros Pharmaceuticals Nears Milestone in HR-MDS Treatment Trial

In a significant development for the biopharmaceutical industry, Syros Pharmaceuticals has announced the successful completion of patient enrollment in the SELECT-MDS-1 Phase 3 clinical trial. The trial aims to evaluate...

Mar 25, 2024 • Major Pharmaceutical Preparations Industry Product Service News NASDAQ

Syros Pharmaceuticals Sets High 2024 Milestones for Tamibarotene Amid Financial Hurdles

Syros Pharmaceuticals, a prominent biopharmaceutical company headquartered in Cambridge, Massachusetts, has recently released its anticipated milestones for the year 2024. As a leader in the development of innovative tr...

Jan 8, 2024 • Major Pharmaceutical Preparations Industry Business Update NASDAQ

Syros Pharmaceuticals Announces Pricing of $45 Million Underwritten Offering, Shares Surge 17.51% YTD

Syros Pharmaceuticals, a leading biopharmaceutical company dedicated to revolutionizing the treatment of hematologic malignancies, recently revealed the pricing details of its underwritten offering of common stock and p...

Dec 19, 2023 • Major Pharmaceutical Preparations Industry Stock Transactions NASDAQ

Tamibarotene Shows Promising Results in Phase 2 Clinical Trial for Acute Myeloid Leukemia, Boosting Syros Pharmaceuticals Amid Revenue Decline

Syros Pharmaceuticals, a leading biopharmaceutical company focused on revolutionizing treatment options for hematologic malignancies, has recently released encouraging initial data from its ongoing SELECT-AML-1 Phase 2...

Dec 6, 2023 Product Service News NASDAQ

Syros Pharmaceuticals Releases Q3 2023 Financial Results and Charts Path for Future Growth

Syros Pharmaceuticals, a leading biopharmaceutical company dedicated to revolutionizing the treatment of hematologic malignancies, recently disclosed its financial results for the third quarter ended September 30, 2023....

Nov 14, 2023 Business Update NASDAQ